These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 9669810)
1. Prognostic significance of tumor necrosis factors and their receptors in nonsmall cell lung carcinoma. Tran TA; Kallakury BV; Ambros RA; Ross JS Cancer; 1998 Jul; 83(2):276-82. PubMed ID: 9669810 [TBL] [Abstract][Full Text] [Related]
2. Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer. Gregorc V; Spreafico A; Floriani I; Colombo B; Ludovini V; Pistola L; Bellezza G; Viganò MG; Villa E; Corti A Cancer; 2007 Aug; 110(4):845-53. PubMed ID: 17599769 [TBL] [Abstract][Full Text] [Related]
3. Tumour necrosis factor-alpha and transforming growth factor-beta are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL-2-mediated neovascularization. Boldrini L; Calcinai A; Samaritani E; Pistolesi F; Mussi A; Lucchi M; Angeletti CA; Basolo F; Fontanini G Br J Cancer; 2000 Aug; 83(4):480-6. PubMed ID: 10945495 [TBL] [Abstract][Full Text] [Related]
4. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival. Liao WT; Wang X; Xu LH; Kong QL; Yu CP; Li MZ; Shi L; Zeng MS; Song LB Cancer; 2009 Apr; 115(7):1507-17. PubMed ID: 19170237 [TBL] [Abstract][Full Text] [Related]
5. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Arinaga M; Noguchi T; Takeno S; Chujo M; Miura T; Uchida Y Cancer; 2003 Jan; 97(2):457-64. PubMed ID: 12518370 [TBL] [Abstract][Full Text] [Related]
6. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. Decaussin M; Sartelet H; Robert C; Moro D; Claraz C; Brambilla C; Brambilla E J Pathol; 1999 Aug; 188(4):369-77. PubMed ID: 10440746 [TBL] [Abstract][Full Text] [Related]
7. Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma. Kim JS; Han J; Shim YM; Park J; Kim DH Cancer; 2005 Nov; 104(9):1825-33. PubMed ID: 16177988 [TBL] [Abstract][Full Text] [Related]
8. Increased expression of collagen XVIII and its prognostic value in nonsmall cell lung carcinoma. Chang H; Iizasa T; Shibuya K; Iyoda A; Suzuki M; Moriya Y; Liu TL; Hiwasa T; Hiroshima K; Fujisawa T Cancer; 2004 Apr; 100(8):1665-72. PubMed ID: 15073855 [TBL] [Abstract][Full Text] [Related]
9. Correlation between survivin expression and prognosis in non-small cell lung cancer. Atikcan S; Unsal E; Demirag F; Köksal D; Yilmaz A Respir Med; 2006 Dec; 100(12):2220-6. PubMed ID: 16650973 [TBL] [Abstract][Full Text] [Related]
10. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer. De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780 [TBL] [Abstract][Full Text] [Related]
11. Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer. Zhang Z; Ma J; Li N; Sun N; Wang C Ann Thorac Surg; 2006 Jul; 82(1):243-8. PubMed ID: 16798222 [TBL] [Abstract][Full Text] [Related]
12. Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer. Tsubochi H; Sato N; Hiyama M; Kaimori M; Endo S; Sohara Y; Imai T Ann Thorac Surg; 2006 Oct; 82(4):1198-204. PubMed ID: 16996907 [TBL] [Abstract][Full Text] [Related]
13. The expression of cyclins D1 and E in predicting short-term survival in squamous cell carcinoma of the lung. Anton RC; Coffey DM; Gondo MM; Stephenson MA; Brown RW; Cagle PT Mod Pathol; 2000 Nov; 13(11):1167-72. PubMed ID: 11106072 [TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer. Carrillo de Santa Pau E; Arias FC; Caso Peláez E; Muñoz Molina GM; Sánchez Hernández I; Muguruza Trueba I; Moreno Balsalobre R; Sacristán López S; Gómez Pinillos A; del Val Toledo Lobo M Cancer; 2009 Apr; 115(8):1701-12. PubMed ID: 19197998 [TBL] [Abstract][Full Text] [Related]
15. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Spierings DC; de Vries EG; Timens W; Groen HJ; Boezen HM; de Jong S Clin Cancer Res; 2003 Aug; 9(9):3397-405. PubMed ID: 12960128 [TBL] [Abstract][Full Text] [Related]
16. Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer. Derin D; Soydinç HO; Guney N; Tas F; Camlica H; Duranyildiz D; Yasasever V; Topuz E Lung Cancer; 2008 Feb; 59(2):240-5. PubMed ID: 17875341 [TBL] [Abstract][Full Text] [Related]
17. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer. Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846 [TBL] [Abstract][Full Text] [Related]
18. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results. Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205 [TBL] [Abstract][Full Text] [Related]
19. Significance of expression of TGF-beta in pulmonary metastasis in non-small cell lung cancer tissues. Saji H; Nakamura H; Awut I; Kawasaki N; Hagiwara M; Ogata A; Hosaka M; Saijo T; Kato Y; Kato H Ann Thorac Cardiovasc Surg; 2003 Oct; 9(5):295-300. PubMed ID: 14672525 [TBL] [Abstract][Full Text] [Related]
20. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance. Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]